Health · 44 views
Ixekizumab + Tirzepatide boosts psoriatic arthritis outcomes more than Ixekizumab monotherapy
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits over ixekizumab (IXE) alone in adults with active psoriatic arthritis (PsA) who are overweight or have obesity, according to a study presented at the annual meeting of the…
Summary
Ixekizumab plus tirzepatide (IXE+TZP) shows significant benefits over ixekizumab (IXE) alone in adults with active psoriatic arthritis (PsA) who are overweight or have obesity, according to a study presented at the annual meeting of the American Academy of Dermatology, held from March 27 to 31 in Denver. Joseph F.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- RFK Jr. eases access to unproven peptides despite opposition from FDA scientistsContinue reading
- Listen to the Latest ‘KFF Health News Minute’Continue reading
- Ahead of midterms, Missourians defend transgender healthcareContinue reading
- New blood test can detect changes associated with Alzheimer's diseaseContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow